share_log

10-Q: Quarterly report

10-Q: Quarterly report

10-Q：季度报表
美股sec公告 ·  05/14 16:10
Moomoo AI 已提取核心信息
Conduit Pharmaceuticals Inc. (Conduit) reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $3.6 million, compared to a net loss of $1.7 million in the same period the previous year. Research and development expenses were $128,000, attributed to the development of co-crystals of AZD1656, a compound targeting autoimmune diseases. General and administrative expenses increased by 87% to $2.8 million, primarily due to higher salaries and stock compensation expense, as well as insurance-related costs. Other income and expenses resulted in a net expense of $597,000, mainly due to the issuance of warrants. Interest expense was reported at $119,000. Conduit's cash flow from operating activities was a net use of $2.4 million. The company did not engage in investing activities and had no cash flow from financing activities for the quarter. Conduit's management is seeking additional capital to fund operations and continue as a going concern. The company's future plans include advancing clinical assets through development and seeking partnerships for licensing opportunities.
Conduit Pharmaceuticals Inc. (Conduit) reported its financial performance for the quarter ended March 31, 2024. The company experienced a net loss of $3.6 million, compared to a net loss of $1.7 million in the same period the previous year. Research and development expenses were $128,000, attributed to the development of co-crystals of AZD1656, a compound targeting autoimmune diseases. General and administrative expenses increased by 87% to $2.8 million, primarily due to higher salaries and stock compensation expense, as well as insurance-related costs. Other income and expenses resulted in a net expense of $597,000, mainly due to the issuance of warrants. Interest expense was reported at $119,000. Conduit's cash flow from operating activities was a net use of $2.4 million. The company did not engage in investing activities and had no cash flow from financing activities for the quarter. Conduit's management is seeking additional capital to fund operations and continue as a going concern. The company's future plans include advancing clinical assets through development and seeking partnerships for licensing opportunities.
Conduit Pharmicals Inc.（Conduit）公布了截至2024年3月31日的季度财务业绩。该公司的净亏损为360万美元，而去年同期的净亏损为170万美元。研发费用为12.8万美元，这归因于开发针对自身免疫性疾病的化合物 AZD1656 的共晶体。一般和管理费用增加了87％，达到280万美元，这主要是由于工资和股票补偿费用以及保险相关成本的增加。其他收入和支出导致净支出为597,000美元，主要是由于发行认股权证。据报道，利息支出为11.9万美元。Conduit的经营活动现金流净使用额为240万美元。该公司没有从事投资活动，本季度也没有来自融资活动的现金流。Conduit的管理层正在寻求额外的资金来为运营提供资金，并将继续作为持续经营企业。该公司的未来计划包括通过开发来增加临床资产，以及寻求合作伙伴关系以获得许可机会。
Conduit Pharmicals Inc.（Conduit）公布了截至2024年3月31日的季度财务业绩。该公司的净亏损为360万美元，而去年同期的净亏损为170万美元。研发费用为12.8万美元，这归因于开发针对自身免疫性疾病的化合物 AZD1656 的共晶体。一般和管理费用增加了87％，达到280万美元，这主要是由于工资和股票补偿费用以及保险相关成本的增加。其他收入和支出导致净支出为597,000美元，主要是由于发行认股权证。据报道，利息支出为11.9万美元。Conduit的经营活动现金流净使用额为240万美元。该公司没有从事投资活动，本季度也没有来自融资活动的现金流。Conduit的管理层正在寻求额外的资金来为运营提供资金，并将继续作为持续经营企业。该公司的未来计划包括通过开发来增加临床资产，以及寻求合作伙伴关系以获得许可机会。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息